MIRA Pharmaceuticals

MIRA

Drug Manufacturers - General · Healthcare

Exchange

NASDAQ Capital Market

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

MIRA Pharmaceuticals is a small clinical-stage drug company, meaning it is still developing medicines and has not yet sold any products. The company is focused on creating new treatments for neurological and psychiatric conditions, including anxiety, depression, and cognitive disorders. Its lead experimental drug, MIRA-55, is a modified form of a compound related to THC, the active ingredient in cannabis, designed to provide therapeutic benefits with fewer unwanted side effects.

Because MIRA has no approved products, it currently generates no revenue and funds its operations through stock offerings and outside investment. The company is based in the United States and is very small, with a market cap near zero and significant ongoing losses, which is typical for early-stage biotech firms. The biggest risk the company faces is clinical and financial: if its drug candidates fail in trials or it cannot raise enough money to continue research, the business could run out of funding before reaching the market.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+72.7% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

36.1%ownership

Insiders own a meaningful stake in the company

Cash Runway

~23 months

$9M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Adequate runway but may need to raise capital within 2 years

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-11.8%

Weak — -11.8% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial